Genentech is continuing its summer of downsizing and cost-cutting, this time with plans to terminate a cell therapy deal ...

After years of striking acquisitions to build up its site network, Headlands Research has now been bought itself.  | After ...

After an FDA rejection in May, Stealth BioTherapeutics has resubmitted a new drug application for its investigational ...

Baxter’s efforts this summer to correct high-risk issues with its infusion pumps has gotten more complicated.  | Last month ...

Reunion Neuroscience’s psychedelic has reduced the symptoms of postpartum depression in a phase 2 study, setting up the ...

Palatin has a research program in DR, and more specifically, in diabetic macular edema (DME), a complication of DR that ...

Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Yet another biotech is facing a delay from the Food and Drug Administration as the agency reels from intense staffing cuts. | Yet another biotech is facing a delay from the Food and Drug ...

Jayanta Bhattacharya, M.D., Ph.D., director of the National Institutes of Health (NIH), has called on the agency’s scientific ...

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

Omeros’ efforts to get its transplant drug to market have already suffered one FDA rejection. | Omeros’ efforts to get its ...